Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers. (March 2021)

• Record Type: Journal Article
• Authors: Benkova, Katerina; Mihalyova, Jana; Hajek, Roman; Jelinek, Tomas
• Is Part Of: Blood reviews. Volume 46(2021)
• Publication Date: 2021-03
• Subjects: Selinexor -- Exportin 1 protein -- Selective inhibitors of nuclear export -- Myeloma -- Lymphoma -- Leukemia; Hematology -- Periodicals; Hematology -- Periodicals; Hématologie -- Périodiques; Hematology; Electronic journals; Periodicals; 616.15
• DOI: 10.1016/j.blre.2020.100758
• Languages: English
• ISSNs: 0268-960X

Abstract

Abstract: Exportin 1 (XPO1), also known as chromosome maintenance 1 protein (CRM1), is the main transporter for hundreds of proteins like tumor suppressors, growth regulatory factors, oncoprotein mRNAs and others. Its upregulation leads to the inactivation of the tumor suppressor anti-neoplastic function in many cancers and logically is associated with poor prognosis. Selective inhibitors of nuclear export (SINE) are a new generation of XPO1 inhibitors that are being investigated as a promising targeted anti-cancer therapy. Selinexor is the first generation of SINE compounds that is being evaluated in many clinical trials involving solid tumors and hematological malignancies with its two approved indications for relapsed multiple myeloma and relapsed diffuse large B-cell lymphoma. Here, we comprehensively review the current knowledge of selinexor and next generations of the SINE compounds in lymphoid and myeloid malignancies.